Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
<p>Abstract</p> <p>Background/aims</p> <p>Breast cancer metastasis suppressor 1 (BRMS1) blocks metastasis in melanoma xenografts; however, its usefulness as a biomarker in human melanomas has not been widely studied. The goal was to measure BRMS1 expression in benign ne...
Main Authors: | Slipicevic Ana, Holm Ruth, Emilsen Elisabeth, Ree Rosnes Anne, Welch Danny R, Mælandsmo Gunhild M, Flørenes Vivi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-02-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/12/73 |
Similar Items
-
Soluble AXL as a marker of disease progression and survival in melanoma.
by: Karine Flem-Karlsen, et al.
Published: (2020-01-01) -
BRMS1 in Gliomas—An Expression Analysis
by: Jonas Feldheim, et al.
Published: (2023-05-01) -
Bayesian Item Response Modeling in R with brms and Stan
by: Paul-Christian Bürkner
Published: (2021-11-01) -
Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival
by: Cui Rui-Xue, et al.
Published: (2012-08-01) -
Retraction: BRMS1 Suppresses Glioma Progression by Regulating Invasion, Migration and Adhesion of Glioma Cells
by: The Editors
Published: (2022-01-01)